Myeloma: Control or Cure? Dr. Barlogie's Perspective
Read Transcript
Download Transcript 
Share This Video
Take Our SurveyWith the emergence of multiple myeloma treatments in favor of making the disease a chronic condition, many question whether a cure is a priority. Dr. Bart Barlogie, a noted myeloma expert from the University of Arkansas (UAMS), shares his thoughts on the curability of myeloma and controversy surrounding treatment motives. He speaks in depth about the challenges of measuring curability–including co-morbidity–and why the approach of treatment with novel agents for high-risk patients must be reevaluated. Dr. Barlogie talks about successful remissions, unfortunate relapses, overall survival and learnings throughout his career. As the debate continues among experts, Dr. Barlogie helps us understand what Myelodysplasia (MDS) and transplant mean for patients living with multiple myeloma in an ever changing treatment landscape.
Get Email Updates:
Privacy Policy
Experts & Guests
|
Bart Barlogie, M.D., Ph.D.
Director of the UAMS Myeloma Institute, University of Arkansas for Medical Sciences
Dr. Bart Barlogie is professor of medicine and pathology at the University of Arkansas for Medical Sciences (UAMS) in Little Rock. He holds position as the director of the UAMS Myeloma Institute for Research and Therapy. Dr. Barlogie is an internationally recognized authority on the use of novel therapies to combat multiple myeloma for improved patient outcome. On the faculty...
more >
|
|
|
